E0 ConsensusPreliminaryPEM not requiredReview-NarrativePeer-reviewedMachine draft
Standard · 3 min
Psychotropic treatment of chronic fatigue syndrome and related disorders.
Goodnick, P J, Sandoval, R · The Journal of clinical psychiatry · 1993
Quick Summary
This review examined whether antidepressant medications can help people with ME/CFS and fibromyalgia, since depression often occurs alongside these conditions. Researchers looked at 23 studies and found that certain antidepressants—particularly at lower doses than used for depression alone—may help reduce both fatigue and pain symptoms. Different types of antidepressants appeared to work better for different symptoms: some were better for pain relief, while others were better for mood.
Why It Matters
This review provides early evidence that antidepressants may benefit ME/CFS patients through mechanisms related to underlying neurochemical dysfunction rather than psychiatric comorbidity alone. Understanding which antidepressant classes target specific symptoms (pain versus fatigue/mood) could help clinicians personalize treatment and improve outcomes for patients who have both depression and ME/CFS.
Observed Findings
Antidepressants appear effective in some CFS and fibromyalgia patients at doses lower than those used for major depression (e.g., amitriptyline 25–75 mg/day).
Serotonergic antidepressants (clomipramine) were more successful at alleviating pain symptoms.
Catecholaminergic agents (maprotiline, bupropion) appeared particularly effective for depression symptoms.
Shared neurochemical disturbances may underlie both CFS and major depression.
Respone patterns differed by drug mechanism, suggesting symptom-specific targets.
Inferred Conclusions
Antidepressants may work in CFS/fibromyalgia due to shared neurochemical abnormalities rather than primary psychiatric illness.
Different antidepressant classes targeting different neurotransmitter systems may preferentially treat different symptom clusters (pain vs. mood).
Lower doses of antidepressants may be needed for CFS compared to major depression, suggesting different pathophysiology.
Further investigation linking neurochemical mechanisms to antidepressant selection could optimize treatment outcomes.
Remaining Questions
What specific neurochemical abnormalities are present in CFS and how do they differ from those in major depression?
What This Study Does Not Prove
This review does not establish that depression causes ME/CFS or vice versa—shared neurochemistry may indicate a common underlying pathology rather than causal relationships. The studies reviewed vary widely in quality and methodology, so findings cannot be generalized confidently to all ME/CFS patients. This review also does not prove antidepressants treat core ME/CFS pathology; they may only manage associated symptoms.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Method Flag:PEM Not DefinedWeak Case DefinitionMixed Cohort
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →